Nachrichten zur Swedish Orphan Biovitrum AB Aktie

Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today that revenue and adjusted EBITA margin for the full year 2025 were higher than previous outlook. Full-year revenue was approximately SEK 28.2 B, representing approximately 15 per cent growth at constant exchange rate (CER)[1]. Adjusted EBITA margin1,[2] was approximately 40 per cent…

…

…

…

OTTAWA, Ontario--(BUSINESS WIRE)--Kinaxis® (TSX:KXS), ein Weltmarktführer im Bereich der End-to-End-Lieferkettenkoordination, gab heute bekannt, dass Swedish Orphan Biovitrum AB (Sobi), ein…

…

Drugmaker Swedish Orphan Biovitrum AB’s Chief Executive Officer Guido Oelkers said he doesn’t think tariff threats on the pharmaceutical industry…

Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today that revenue for the full year 2024 was higher than previous…

The Swedish Orphan Biovitrum AB (publ) (Sobi®) EGM was convened today on 11 December 2024. In accordance with the Nomination Committee’s proposals,…

The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting…

…

As per 30 September 2024, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 356,000,049…

…

Bergen, Norway, May 28, 2024, – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors…

Swedish Orphan Biovitrum AB (publ) (Sobi[®]) has successfully completed the inaugural issue of senior unsecured bonds of SEK 3 billion under…

Swedish Orphan Biovitrum AB (publ) (Sobi[®]) has established a medium term note programme with a framework amount of SEK 10…

…

Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024 First Quarter 2024 •          Total revenue increased…